Q3 business highlights at a glance

This podcast summary was generated with the assistance of AI tools based on the Q3/2025 earnings call transcript. While reviewed for accuracy, it may contain errors or interpretations not intended by Teva. For the official record, please refer to the full earnings call transcript.

Share this article:

You might also be interested

Q1 2026 Earnings hightlights, Listen to the AI - powered call summary

Teva in Q1 2026: Our transformation at a glance
teva

Multiple System Atrophy (MSA) – Teva Therapeutic Areas
Man sitting on a sofa holding his stomach as if in discomfort, with a green DNA strand graphic overlay.

What to Know About Celiac Disease
Teva scientist interacting with a large green abstract network graphic illustrating biological pathways and potential pathways for business growth.

Sustaining Teva’s Generics Powerhouse in the Acceleration Phase
Teva scientist using microscope working on research for innovative medicines

Step Up Innovation
Teva scientist looking at stylized DNA strand representing acceleration phase of pivot to growth strategy

Pivot to Growth: The Acceleration Phase
Female Teva scientist reflecting on how innovative medicines in growth engine therapeutic areas will help patients worldwide

Delivering on Growth Engines
podcast

Teva in 2025: Innovation drives third consecutive year of growth
Evan Lippman, Teva’s Executive Vice President of Business Development

Meet Our
People

“I Think People are Starting to Get That There’s a Lot of Upside at Teva”

Teva Rise: Accelerating Pharma Innovation Globally